Immunosuppressants Market: By Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Immunosuppressants Market size was valued at USD 62.46 billion in 2023 and is poised to grow at a CAGR of 14.2% from 2024-2030. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in organ transplantation, and autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others.  Moreover, immunosuppressants are also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis.

Immunodeficiency is the major adverse effect associated with immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects of immunosuppressants. The immunosuppressants market is growing at a significant CAGR owing to an increase in the prevalence of autoimmune disorders and the incidence of organ transplantation. For instance, According to the World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was an increase of about 1.8% from 2013. Furthermore, various pipeline products in the market are also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies to increase their revenue in the immunosuppressants market.

Immunosuppressants Market Key Developments:
  • In September 2017, Zydus Cadila received FDA final approval for Mycophenolate Mofetil Immunosuppressant injection
  • In April 2017, Sanofi received FDA approval for a Thymoglobulin immunosuppressant drug used for the prevention of acute kidney transplant rejection.

Immunosuppressants Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

14.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Immunosuppressants Market Dynamics

Increase in the incidence of organ failure and there by rising demand for organ transplantation, technological advancements in organ transplantation procedures, and increase in the prevalence of autoimmune diseases are the factors anticipated to fuel the immunosuppressants market over the forecast period. Moreover, favourable reimbursement policies for immunosuppressants, development of newer therapeutic drugs, and various pipeline products might fuel the immunosuppressants market over the forecast period. However, stringent regulatory policies for drug approval, alternative therapies such as stem cell therapy for immunosuppression, and lack of awareness about immunosuppressants are the factors expected to hamper the growth of immunosuppressants market over the forecast period.

Immunosuppressants Market Segmentation

By Drug Class
  • Corticosteroids
  • Monoclonal Antibodies (mAbs)
  • Calcineurin Inhibitors
  • mTOR Inhibitors
  • Anti-Proliferative Agents
  • Others
By Indication
  • Organ Transplantation
  • Autoimmune Disorders
  • Non-Autoimmune Inflammatory Diseases
By Route Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Frequently Asked Questions

The immunosuppressants market size was valued at USD 61.54 billion in 2023

Technological Advancements in Tissue Engineering and Organ Transplantations

Asia Pacific is the fastest-growing for immunosuppressants market

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Immunosuppressants Market Introduction 
2.1.Global Immunosuppressants Market  - Taxonomy
2.2.Global Immunosuppressants Market  - Definitions
2.2.1.By Drug Class
2.2.2.By Indication
2.2.3.By Route Administration
2.2.4.By Distribution Channel
2.2.5.Region
3.Global Immunosuppressants Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Immunosuppressants Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Immunosuppressants Market  By By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Corticosteroids
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Monoclonal Antibodies (mAbs)
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Calcineurin Inhibitors
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. mTOR Inhibitors
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Anti-Proliferative Agents
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6.Global Immunosuppressants Market  By By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Organ Transplantation
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Autoimmune Disorders
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Non-Autoimmune Inflammatory Diseases
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Immunosuppressants Market  By By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parenteral
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Immunosuppressants Market  By By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital pharmacies
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail pharmacies
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online pharmacies
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Immunosuppressants Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Corticosteroids
10.1.2.Monoclonal Antibodies (mAbs)
10.1.3.Calcineurin Inhibitors
10.1.4.mTOR Inhibitors
10.1.5.Anti-Proliferative Agents
10.1.6.Others
10.2.  By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Organ Transplantation
10.2.2.Autoimmune Disorders
10.2.3.Non-Autoimmune Inflammatory Diseases
10.3.  By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parenteral
10.4.  By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital pharmacies
10.4.2.Retail pharmacies
10.4.3.Online pharmacies
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. By Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Corticosteroids
11.1.2.Monoclonal Antibodies (mAbs)
11.1.3.Calcineurin Inhibitors
11.1.4.mTOR Inhibitors
11.1.5.Anti-Proliferative Agents
11.1.6.Others
11.2.  By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Organ Transplantation
11.2.2.Autoimmune Disorders
11.2.3.Non-Autoimmune Inflammatory Diseases
11.3.  By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parenteral
11.4.  By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital pharmacies
11.4.2.Retail pharmacies
11.4.3.Online pharmacies
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. By Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Corticosteroids
12.1.2.Monoclonal Antibodies (mAbs)
12.1.3.Calcineurin Inhibitors
12.1.4.mTOR Inhibitors
12.1.5.Anti-Proliferative Agents
12.1.6.Others
12.2.  By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Organ Transplantation
12.2.2.Autoimmune Disorders
12.2.3.Non-Autoimmune Inflammatory Diseases
12.3.  By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parenteral
12.4.  By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital pharmacies
12.4.2.Retail pharmacies
12.4.3.Online pharmacies
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. By Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Corticosteroids
13.1.2.Monoclonal Antibodies (mAbs)
13.1.3.Calcineurin Inhibitors
13.1.4.mTOR Inhibitors
13.1.5.Anti-Proliferative Agents
13.1.6.Others
13.2.  By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Organ Transplantation
13.2.2.Autoimmune Disorders
13.2.3.Non-Autoimmune Inflammatory Diseases
13.3.  By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parenteral
13.4.  By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital pharmacies
13.4.2.Retail pharmacies
13.4.3.Online pharmacies
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. By Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Corticosteroids
14.1.2.Monoclonal Antibodies (mAbs)
14.1.3.Calcineurin Inhibitors
14.1.4.mTOR Inhibitors
14.1.5.Anti-Proliferative Agents
14.1.6.Others
14.2.  By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Organ Transplantation
14.2.2.Autoimmune Disorders
14.2.3.Non-Autoimmune Inflammatory Diseases
14.3.  By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Parenteral
14.4.  By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital pharmacies
14.4.2.Retail pharmacies
14.4.3.Online pharmacies
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.GlaxoSmithKline Plc. (U.K.)
15.2.2.Novartis AG (Switzerland)
15.2.3.Sanofi S.A. (France)
15.2.4.Pfizer, Inc. (U.S.)
15.2.5.Bristol Myers Squibb (U.S.)
15.2.6.F. Hoffmann La Roche Ltd. (Switzerland)
15.2.7.Astellas Pharma, Inc. (Japan)
15.2.8.Zydus Cadila (India)
15.2.9.Genzyme Corporation (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 
  • GlaxoSmithKline Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi S.A. (France)
  • Pfizer, Inc. (U.S.)
  • Bristol Myers Squibb (U.S.)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Astellas Pharma, Inc. (Japan)
  • Zydus Cadila (India)
  • Genzyme Corporation (U.S.)

Adjacent Markets